Program
KAT2A/KAT2B Degrader AUTX-703
Its studies are mostly in Leukemia, Myeloid, Acute, led by Auron Therapeutics.
Furthest: phase 1, since Feb 6, 20251 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Auron Therapeutics | 11 open or running | phase 1since Feb 6, 2025 | Feb 6, 2025 | Apr 2027phase 1 · NCT06846606 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2025First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT06846606 · 69 planned · United States
Ahead
- Apr 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06846606
TargetBeta
“An orally bioavailable, small molecule degrader of the histone acetyltransferases and transcriptional activators lysine acetyltransferase 2A (KAT2A) and its paralog lysine acetyltransferase 2B (KAT2B), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| KAT2A/B Inhibitor PF-07994525 | Pfizer | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06846606Leukemia, Myeloid, Acute · United States | 1 | Recruiting | Apr 2027 | 69 |
How it is read
Names in the registry
- “AUTX-703”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.